RxDoctor Payments Data

Jonathan Zelenak, DO

Ophthalmology · Livonia, MINPI 1972035483

Payments from drug & device makers

$2,261in general payments, 2019–2025

Across 64 payments — averaging $35.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • AbbVie$189
  • Biotissue Holdings Inc.$170
  • Regeneron Healthcare Solutions, Inc.$151
  • Sun Pharmaceutical Industries Inc.$111
  • Bausch & Lomb Americas Inc.$87
  • plus $330 from 12 others

What the payments were for

  • Food & beverage$2,24199%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,261 in reported general payments places this provider in the 65th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$149,010
Medicare patients
269
Services billed
1,336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CequaCyclosporine13$9,460
LumiganBimatoprost16$8,249
SimbrinzaBrinzolamide/Brimonidine Tart29$7,073
Brimonidine Tartrate53$6,200
Latanoprost263$5,834
Prednisolone Acetate122$5,249
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$4,132
Brinzolamide12$3,551
Tobramycin-DexamethasoneTobramycin/Dexamethasone25$2,101
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat58$1,641
Ofloxacin39$764
Timolol Maleate19$733
Dorzolamide Hcl20$456
Ciprofloxacin Hcl37$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sun Pharmaceutical Industries Inc.Cequa$111$9,46013 claims
AbbVieLumigan$189$8,24916 claims
AlconSimbrinza$1,222$7,07329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →